Evidence map›Paper›PMID 26722027›Full record

ArticleAnticancer research2016

A Novel Sirtuin-3 Inhibitor, LC-0296, Inhibits Cell Survival and Proliferation, and Promotes Apoptosis of Head and Neck Cancer Cells.

Turki Y Alhazzazi, Pachiyappan Kamarajan, Yanli Xu, Teng Ai, Liqiang Chen, Eric Verdin, Yvonne L Kapila

Abstract read
PubMed Full text at PMC
In one paragraph

Article in Anticancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Epigenetic meets metabolism: novel vulnerabilities to fight cancer.Cell communication and signaling : CCS · 2023
    Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Turki Y AlhazzaziDepartment of Oral Biology, King Abdulaziz University, Faculty of Dentistry, Jeddah, Saudi Arabia Department of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI, U.S.A.
Pachiyappan KamarajanDepartment of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI, U.S.A.
Yanli XuCenter for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, MN, U.S.A.
Teng AiCenter for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, MN, U.S.A.
Liqiang ChenCenter for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, MN, U.S.A.
Eric VerdinGladstone Institute of Virology and Immunology, University of California, San Francisco, CA, U.S.A.
Yvonne L KapilaDepartment of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI, U.S.A. ykapila@umich.edu.

Funding

Biomarkers of Aggressive Oral CancerR56DE023333 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KAPILA, YVONNE L · 2013 to 2014
$467k
Fibronectin Regulation of AnoikisR56DE014429 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KAPILA, YVONNE L · 2010 to 2010
$367k
NIDCR NIH HHS R56 DE014429NIDCR NIH HHS R56DE014429NIDCR NIH HHS R56 DE023333PHS HHS R01DEO14429
6 · The paper itself

Abstract

backgroundThe survival rate of patients with head and neck squamous cell carcinoma (HNSCC) stands at approximately 50% and this has not improved in decades. This study developed a novel sirtuin-3 (SIRT3) inhibitor (LC-0296) and examined its role in altering HNSCC tumorigenesis. MATERIALS AND

methodsThe effect of the SIRT3 inhibitor, LC-0296, on cell survival, proliferation, and apoptosis, and reactive oxygen species levels in HNSCC cells were studied.

resultsLC-0296 reduces cell proliferation and promotes apoptosis of HNSCC cells but not of normal human oral keratinocytes. This inhibitory effect is mediated, in part, via modulation of reactive oxygen species levels. Additionally, LC-0296 works synergistically to increase the sensitivity of HNSCC cells to radiation and cisplatin treatment.

conclusionDevelopment of novel SIRT3 inhibitors, such as LC-0296, might enable the development of new targeted therapies to treat and improve the survival rate of patients with head and neck cancer.

Indexed as

Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsApoptosisCarcinoma, Squamous CellCell Line, TumorCell ProliferationChemoradiotherapyCisplatinDose-Response Relationship, DrugHead and Neck NeoplasmsHeterocyclic Compounds, 4 or More RingsHistone Deacetylase InhibitorsHumansIndolesKeratinocytesLaryngeal NeoplasmsAntineoplastic AgentsCisplatinHeterocyclic Compounds, 4 or More RingsHistone Deacetylase InhibitorsIndolesLC-0296Reactive Oxygen SpeciesSIRT3 protein, humanSirtuin 3HNSCCoral cancerROSSIRT3sirtuin-3sirtuin inhibitorSirtuins

Identifiers

PMID26722027
PMCPMC5417072

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.